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Abstract
Some of the tryptophan catabolites produced through the kynurenine pathway (KP), and more particularly the excitotoxin
quinolinic acid (QA), are likely to play a role in the pathogenesis of Alzheimer’s disease (AD). We have previously shown that
the KP is over activated in AD brain and that QA accumulates in amyloid plaques and within dystrophic neurons. We
hypothesized that QA in pathophysiological concentrations affects tau phosphorylation. Using immunohistochemistry, we
found that QA is co-localized with hyperphosphorylated tau (HPT) within cortical neurons in AD brain. We then investigated
in vitro the effects of QA at various pathophysiological concentrations on tau phosphorylation in primary cultures of human
neurons. Using western blot, we found that QA treatment increased the phosphorylation of tau at serine 199/202, threonine
231 and serine 396/404 in a dose dependent manner. Increased accumulation of phosphorylated tau was also confirmed by
immunocytochemistry. This increase in tau phosphorylation was paralleled by a substantial decrease in the total protein
phosphatase activity. A substantial decrease in PP2A expression and modest decrease in PP1 expression were observed in
neuronal cultures treated with QA. These data clearly demonstrate that QA can induce tau phosphorylation at residues
present in the PHF in the AD brain. To induce tau phosphorylation, QA appears to act through NMDA receptor activation
similar to other agonists, glutamate and NMDA. The QA effect was abrogated by the NMDA receptor antagonist memantine.
Using PCR arrays, we found that QA significantly induces 10 genes in human neurons all known to be associated with AD
pathology. Of these 10 genes, 6 belong to pathways involved in tau phosphorylation and 4 of them in neuroprotection.
Altogether these results indicate a likely role of QA in the AD pathology through promotion of tau phosphorylation.
Understanding the mechanism of the neurotoxic effects of QA is essential in developing novel therapeutic strategies for AD.
Citation: Rahman A, Ting K, Cullen KM, Braidy N, Brew BJ, et al. (2009) The Excitotoxin Quinolinic Acid Induces Tau Phosphorylation in Human Neurons. PLoS
ONE 4(7): e6344. doi:10.1371/journal.pone.0006344
Editor: Christophe Egles, Tufts University, United States of America
Received March 30, 2009; Accepted June 17, 2009; Published July 22, 2009
Copyright:  2009 Rahman et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work has been supported by research grants from: The University of NSW, The Mason Foundation, Alzheimer Australia and the Rebecca Cooper
Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: g.guillemin@unsw.edu.au
. These authors contributed equally to this work.
Introduction
The kynurenine pathway (KP) (Figure 1) is a major route of L-
tryptophan catabolism, resulting in the production of nicotinamide
adenine dinucleotide (NAD
+) and other neuroactive intermedi-
ates[1]. Within the CNS, KP metabolites can have either
neurotoxic or neuroprotective effects. Among them, quinolinic
acid (QA) is perhaps the most important in terms of biological
activity. Stone and Perkins were the first to demonstrated QA
ability to selectively activate neurons expressing NMDA recep-
tors[2]. QA neurotoxicity was then shown by Schwarcz[3]. QA
leads acutely to human neuronal death and chronically to
dysfunction by at least five mechanisms[4] and is known to be
involved in several major neuroinflammatory diseases[4,5,6]
including Alzheimer’s disease (AD)[7].
A hallmark of AD and related tauopathies, such as frontotem-
poral dementia, is the formation and accumulation of neurofibril-
lary tangles (NFTs) within neurons. NFTs are composed of paired
helical filaments (PHF)[8,9] of which the microtubule associated
protein tau in an abnormally hyperphosphorylated state, represents
the major protein component[10,11]. The phosphorylation state of
tau determines its biological activity[12]. Physiologically, tau
promotes the assembly and maintenance of the microtubule
structures. Abnormally hyperphosphorylated tau (HPT) has less
affinity for binding with microtubules. HPT also sequesters normal
tau and other microtubule-associated proteins (MAP1 and MAP2)
and causes disassembly of microtubules[13].
We have previously shown that the KP is activated in AD brain,
leading to an increase in QA production[14]. We also found that in
the hippocampus of AD patients, QA immunoreactivity is detected
in cortical microglia, astrocytes and neurons. Of particular interest
is the high immunoreactivity of QA in the perimeter of senile
plaques and NFTs[15]. Human neurons do not produce QA but
they can take it up[16,17]. The presence of a strong QA
immunoreactivity in vacuoles of hippocampal and entorhinal
neurons[15] ismore likelytheconsequenceofanuptakemechanism
rather than synthesis of QA. Neuronal uptake of QA is likely to be
part of a scavenging process in which activated microglia and/or
infiltrating macrophages release high concentration of QA[16,17].
In vitro, chronic exposure of rat corticostriatal cultures to nanomolar
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Moreover, both low level chronic (350 nM) and high level acute
(1 mM) exposures of human primary neurons to QA are
neurotoxic[19]. Indeed, chronic exposure of human neurons to
QA causes significant structural changes including dendritic
beading, microtubular disruption and a decrease in organelles.
Altogether, the activation of the KP and the over-production of QA
in AD brain, and the co-localization of QA with the histopatho-
logical lesions, particularly the QA accumulation in dystrophic
neurons with the NFTs led us to hypothesize that QA is directly
involved in the hyperphosphorylation of tau.
We found that QA accumulates in neurons and co-localizes with
tau in cortical sections from AD patients. In addition, in vitro
treatment of human foetal neurons with pathophysiological concen-
trations of QA significantlyincreased tau phosphorylation at multiple
phosphorylation sites. Our data also show a decrease in the
expression and activity of serine/threonine protein phosphatase(s),
as the mechanism for tau hyperphosphorylation. We also found that
QA induces at least ten neuronal genes, with some of them known to
be strongly associated with Alzheimer pathology. This study provides
a new insight into the mechanism of QA neurotoxicity and its
important role in the pathogenesis of AD. This work has opened a
new avenue for research on AD, in particular the application of a
novel therapeutic target.
Materials and Methods
Reagents and chemicals
All neuronal cell culture media and additives were from
Invitrogen (Mulgrave, VIC, Australia) unless otherwise stated.
DAPI and mouse monoclonal antibodies (mAb) for b-actin and all
chemicals used for Western blots, immunoprecipitation, Phospha-
tase (PP) activity and immunoblots (unless otherwise mentioned)
were obtained from Sigma-Aldrich Chemical Co. (Sydney, NSW,
Australia). IFN-c was purchased from R&D Systems (Australia),
pAb tau from DAKO, mAbs anti-tau 5 from Abcam, tau AT8 and
Figure 1. Simplified diagram of the kynurenine pathway.
doi:10.1371/journal.pone.0006344.g001
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Peter Davies, Department of Pathology, Albert Einstein, College
of Medicine) and mAb AT270 (Pierce Endogen) were generously
provided by Prof Jurgen Goetz (University of Sydney, NSW,
Australia). Protein phosphatase antibodies PP1c and PP2Ac were
kindly provided by Alistair Sim (University of Newcastle, NSW,
Australia). Secondary anti-mouse IgG, anti-rabbit Alexa -conju-
gated antibodies (594 and 647) and streptavidin-Alexa (594 and
647) were purchased from Molecular Probes (Invitrogen, Eugene,
OR, USA). Biotinylated anti-mouse and anti-rabbit antibodies
were obtained from Vector Laboratories, Burlingame CA USA).
All commercial antibodies were used within the concentration
ranges recommended by the manufacturer.
Ethics statement
Human foetal tissue was obtained following informed written
consent. This has been approved by the Human Ethics
Committees from the University of New South Wales (UNSW
Ethic approval HREC 03187). Blocks of human brain tissue were
obtained from the National Neural Tissue Resource Centre
(NNTRC) and the Australian Brain Bank Network. This study had
the approval of the Human Ethics committee of the University of
Sydney (10-2005/4/8616).
Cell cultures
Human foetal brains were obtained from 16 to 19 week old
foetuses (HREC 03187). Primary cultures of human neurons were
prepared as previously described[16]. Briefly, cells were plated in
culture flasks coated with Matrigel (diluted 1/20 in Neurobasal
medium) and maintained in Neurobasal medium supplemented
with 2% (v/v) B-27 supplement, 2 mM Glutamax, 50 mM
HEPES, 200 IU/ml penicillin G, 200 mg/ml streptomycin
sulphate and 5 mM glucose. Cultures were kept at 37uCa t5 %
CO2 in a humidified atmosphere. The medium was changed once
or twice per week. Neurons were maintained for up to 10 weeks.
Immunocytochemistry for tau
The method has been previously described[16]. Human foetal
neurons were grown at a density of 5610
6 in Permanox chamber-
slides (NUNC) for 2 weeks. Then, cells were fixed with acetone/
methanol (vol/vol) for 20 min at –20uC. Cells were then rinsed 3
times with PBS and a gentle membranous permeabilization was
performed by incubation with 0.025% Triton X 100 in PBS for
10 min at room temperature. After washing, cells were incubated
with 5% normal goat serum (NGS) in PBS for 45 min at room
temperature, rinsed twice with PBS and incubated for 1 h at 37uC
withselected primaryantibody Tau mAbs(Tau 5,AT8 andAT180)
diluted in 5% NGS. Cells were then washed with 5% NGS solution
and incubated for 1 h at 37uC with the appropriate labelled
secondary antibodies (goat anti-mouse IgG or goat anti-rabbit
coupled with Alexa 594). Nuclear staining was performed using
DAPI at 1 mg/ml for 5 min at room temperature. After several
washingswithPBSat37uC,thecoverslipswerequicklymounted on
glass slides with Fluoromount-G, and examined using an Olympus
BX60 fluorescence microscope associated with a digital SensiCam.
The following three controls were performed for each labelling
experiment: 1) isotypic antibody controls for mAbs and serum
control for pAbs, 2) incubation with only the secondary labelled
antibodies, 3) estimation of auto-fluorescence of unlabelled cells.
Quinolinic acid immunohistochemistry in AD brain tissue
Increased QA expression was confirmed in AD tissue. Brain
tissue was acquired through the NSW and Victorian Brain Bank
Networks supported by the National Health and Medical
Research Council. The study has the approval of the Human
Ethics Committees at the University of Sydney. Two age matched
controls and 8 AD cases with a range of neuropathological severity
were examined. Blocks of tissue were taken from 3–5 mm
formalin-fixed coronal slices of the medial temporal lobe, anterior
cingulate and superior frontal cortex. On a CO2 Leica microtome,
blocks were sectioned at 45 mm into 0.1 M Tris buffer (pH 7.4)
containing 0.01% azide. Serial sections were labelled for QA
(mAb, developed by Chemicon for our group) and tau (AT8,
AT180, Pierce Endogen). Free floating sections were washed three
times for 15 minutes each in 50% ethanol then placed in blocking
buffer (0.1 M Tris, 1% bovine serum albumin, 0.01% azide,
0.01% TritonX) for 20 minutes, then incubated in 1u antibody for
24 hrs at 4uC. Sections were washed three times for 15 minutes
each in 0.1 M Tris and incubated in species-specific biotinylated
antibody for 1 hr, washed and placed in streptavidin-Alexa 647 or
594 (Molecular Probes, Invitrogen) diluted 1:100 in 0.1 M Tris
with 0.01% TritonX for 1 hr. For double-immunostaining, the
sections were washed for one hour, incubated in blocking buffer,
then transferred to the second primary antibody solution. For
viewing, sections were mounted on gelatinized glass slides, cover-
slipped in gelatine/glycerol and examined with a Zeiss Axioplan
microscope. Optical sections were taken through the sections at
2 mm intervals and reconstructed using Zeiss Axiovision software
and ImageJ (NIH; Rasband, W.S., ImageJ, U. S. National
Institutes of Health, Bethesda, Maryland, USA, http://rsb.info.
nih.gov/ij/, 1997–2008).
Preparation of neuronal lysates for Western blots
For Western blots, cells were cultured in Matrigel coated 12-
well plates at a density of 1610
6 cells per well in supplemented
Neurobasal medium supplemented (as described above). Neurons
were incubated with various concentrations of QA (ranging from
50 to 1200 nM) for 72 hours. Control cultures were kept in the
medium alone. Okadaic acid (100 nM) was used as positive
control for tau phosphorylation. In a separate experiment, neurons
were cultured with 500 nM each of NMDA receptor agonists (QA,
glutamate, NMDA) and antagonists (memantine, AP-5 and MK-
801) for 72 hrs. Cells were lysed in 500 ml of RIFA buffer, (50 mM
Tris, pH 7.4, 150 mM NaCl, 1% NP-40, 5 mM EDTA, 0.5%
sod. deoxycholate, 0.1% SDS, 50 nM NaF, 1 mM sodium
vanadate, 2 mg/ml aprotinin, 2 mg/ml pepstatin and 5 mg/ml
leupeptin). The cell lysate was centrifuged at 16000 g for 10
minutes. Protein concentration in the supernatant was determined
by the modified Lowry method and stored at 220uC until used.
SDS-PAGE and immunoblot analyses
20 mg lysate protein was resolved on 10% SDS-PAGE
(NuPAGE 10% from Invitrogen, Carlsbad CA USA) in sample
buffer. Protein was transferred onto PVDF membranes; the
membranes were blocked with 5% milk in TBS for one hour and
incubated with primary antibody overnight at 4uC. The primary
antibodies used are described in Table 1. After incubation, the
membranes were rinsed several times, washed with TBS-tween
three times (10 minutes each), and then two times with TBS only.
The membranes were then incubated with the secondary antibody
for 4 hours at RT, washed as before and developed either with
ECL or Chemidox, (Biorad, Hercules, CA, USA) according to the
manufacturer instructions. Blots were quantified using the
Quantity One 4.6.1 software from Biorad and ImageJ (NIH;
Rasband, W.S., ImageJ, U. S. National Institutes of Health,
Bethesda, Maryland, USA, http://rsb.info.nih.gov/ij/, 1997–
2008).
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For phosphatase activity, cells were cultured as described above
and lysed in the phosphatase activity buffer (50 mM Tris, pH 7.5,
150 mM NaCl, 1% NP-40, 1 mM PMSF, 1 mM benzamidine,
10 mM beta-mercaptoethanol (bME), 2 mg/ml aprotinin, 2 mg/
ml pepstatin and 5 mg/ml leupeptin. Total phosphatase activity
was determined using pNPP (10 mM) as a substrate in 50 mM
Tris-HCl, pH 7.4, 0.1 mg/ml BSA, 3 mM CaCl2,1mM calmod-
ulin and 3 mM MnCl2. The reaction mixture was incubated at
30uC for 30 min and the absorbance measured at 405 nm. PP2A
activity was indirectly measured by using 10 nM OA in the
phosphatase assay buffer and calculating the OA-inhibited
activity.
Immunoprecipitation of PP2A
PP2A was immunoprecipitated according the protocol provided
by Upstate, New York. Briefly, 4 mg of anti-PP2A (Clone 1D6)
(Upstate, New York) was incubated with 100 ml Protein A
Sepharose beads (Amersham/Pharmacia) for 4 hours at 4uCo n
a rotor. The beads were washed with 750 ml TBS 3 times and 2
times with the phosphates lysis buffer. The beads with absorbed
anti-PP2A were incubated with 400 mg lysate protein in a total
volume of 500 ml overnight at 4uC. Unbound proteins were
separated, and the beads were washed (by a brief pulse in table-top
centrifuge) with 750 ml of TBS 3 times. For phosphatase activity,
20 ml beads were pelleted and resuspended in 200 mlo f
phosphatase assay buffer containing 50 mM Tris-HCl, pH 7.4,
3 mM MnCl2 and 10 mM pNPP. The reaction mixture was
incubated at 30uC for 30 min with occasional mixing. At the end
of incubation, the beads were centrifuged and the clear
supernatant was collected into the wells of a 96-well ELISA plate
and the absorbance measured at 405 nm. To measure the amount
of immunoprecipated PP2A, 20 ml of beads were boiled in 46
sample buffer and subjected to SDS-PAGE and Western blots as
described earlier.
PCR array
RT
2 Profiler
TM PCR Array kit were obtained from SuperArray
Bioscience Corporation (Frederick, MD, USA). The Human
Signal Transduction PathwayFinder
TM RT
2Profiler
TM PCR Array
profiles the expression of 84 key genes representative of 18
different signal transduction pathways. Using real-time PCR, we
analysed the expression of a focused panel of genes related to any
of the 18 signal transduction pathways involved in the response of
human primary neurons to QA 150 nM for 24 h.
Results
Quinolinic acid is found in neurons and microglia in AD
cortex
In order to validate the relevance of QA in the mechanism of
tau phosphorylation in the human disease, AD and control tissue
were labelled for QA and tau (AT8, AT180). We confirmed that
QA is found within cortical neurons in AD and, to a substantially
lesser degree, in cortical neurons of elderly controls (Figure 2).
QA is present intrasomally in punctate structures resembling
vesicles and co-localizes with tau-positive fibrillary structures (see
also supplementary Figure S3). QA is also seen throughout the
parenchyma and enriched within plaques in vesicular structures
within microglial processes.
Quinolinic acid treatment induces tau phosphorylation in
cultured human foetal neurons
QA 500 and 1200 nM significantly increased not only the level
of total tau (Figure 3A), but also tau phosphorylation at the Tau-8
and Tau-180 epitopes (Figure 3B and C, respectively), as shown
by the increase in the staining intensity. Cultures treated with
1200 nM QA had less DAPI-stained neurons and a lower intensity
of red staining, compared to control culture and cells treated with
500 nM QA, suggesting that QA 1200 nM is neurotoxic.
To further elucidate the effect of QA on tau phosphorylation,
human foetal neuronal cultures were treated with four different
concentrations of QA for 72 hours and Western blot analyses were
performed using four different phosphorylation specific antibodies.
Details of the experiment are given in the Materials and Methods
and in the figure legend. The results are shown in Figure 4.
Okadaic acid (100 nM) was used as positive control. At this
concentration okadaic acid increased tau phosphorylation with all
the four antibodies studied. Phosphorylation of threonine 181
(AT270) was increased by 20%, serine 199/202 (AT8) by 450%,
threonine 231(AT180) by 400% and serine 396/404 (PHF-1) by
70% over the control levels by OA. QA increased phosphorylation
of serine 199/202 and threonine 231 in a dose dependent manner
over the basal level of phosphorylation in the control cultures
(Figure 4). The effect on threonine 181 and serine 396/404 was
not dose dependent. Phosphorylation of threonine 181 was slightly
Table 1. List of primary antibodies used.
Antibody Type Antigen Source/Reference
Tau polyclonal Total tau DAKO
AT8 monoclonal pS199/202 Innogenetics
AT180 monoclonal pT231 Innogenetics
AT270 monoclonal pT181 Innogenetics/Gotz
PHF-1 monoclonal against pS396/404 Peter Davies
Anti-b-actin monoclonal b-actin Sigma
Anti-PP1 gamma 1 polyclonal PP1c Sigma
Anti-PP2A (clone 1D6) monoclonal PP2Ac Upstate
Anti-PP5 polyclonal PP5 Sigma
Anti-calcineurin (clone CNA1) monoclonal PP2B catalytic subunit Sigma
Anti-Quinolinic acid monoclonal QUIN Chemicon
doi:10.1371/journal.pone.0006344.t001
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used, whereas, phosphorylation of serine 396/404 was increased
substantially by QA at concentrations of 350 nM or higher.
Control cultures showed a substantially higher level of phosphor-
ylation of T181, compared to the other sites tested (Figure 4), and
both QA and OA resulted in a minimal increase in the
phosphorylation of this site over the control level. An interesting
observation was the presence of a higher molecular weight band
Figure 2. Immunodetection of tau and QA in AD sections. QA (red; Alexa 647) and tau (AT8; green; Alexa 594) immunolabelling in control and
AD cingulate cortex (a–e) and hippocampus (f–g). a) Neuritic plaque in the cingulate cortex of a late-stage AD showing the AT8-positive neurites
surrounding by QA-positive cells. The majority of this labelling can be seen in vesicle-like structures within microglial cells, however QA+ neurons in
the plaque vicinity are also present (asterix). b) Co-localisation of an intracellular neurofibrillary tangle and QA. This tangle containing neuron is
contacted by QA+ non-neuronal cells. See also supplementary figure S3 for additional views through this neuron. c) QA-positive vesicles within a
microglia and d) neuron. e) Punctate tau-positivity in a neuron also positive for QA. f) 73-year old neurologically normal control hippocampal CA1
pyramidal cells with very faint immunopositivity for QA. This case had small numbers of entrohinal tangles, but otherwise no other AD-type lesions
were detected. In non-AD cases, QA+ neurons rarely occurred outside the hippocampal-entorhinal sector. g) Hippocampus of a mild AD case (Braak
stage IV) with QA co-localisation with AT8+ intraneuronal tangles. Scale bars 10 mm a–e; 50 mm f–g.
doi:10.1371/journal.pone.0006344.g002
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immunostained for tau phosphorylation with three different antibodies: Line A, staining of total tau using mAb Tau 5 (Abcam); line B, staining of
phosphorylated tau using mAb Tau 180 (Innogenetics); and line C, staining of phosphorylated tau using mAb Tau 8 (Innogenetics). The left column
corresponds to untreated neurons, the middle column to QA 500 nM treated cells and the right column to QA 1200 nM treated cells. The histograms
represent the semi-quantification of the immunostaining intensity. Intensity has been quantified using ImageJ 10.2. This experiment has been
performed in triplicate with primary cultures of neurons prepared from three different brains. Three individual microscopic fields were analysed for
each treatment and the SEM for the data was determined to be ,5%.
doi:10.1371/journal.pone.0006344.g003
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may represent aggregated tau (Figure 5).
Quinolinic acid decreases the expression and activity of
serine/threonine protein phosphatases in cultured
human foetal neurons
In order to investigate if the increased phosphorylation of tau
was due to a decrease in the phosphatase activity of neurons, we
investigated the effect of QA on phosphatase activity using pNPP
as a substrate. We observed an apparent increase in total
phosphatase activity at 100 nm QA, but a dose dependent
decrease thereafter at higher concentrations used (Figure 6A).
Since PP2A is the major phosphatase activity, we indirectly
measured PP2A activity in the presence of 10 nM OA, and
calculated the OA-inhibited (PP2A) activity. QA inhibited OA-
inhibited phosphatase activity in a dose dependent manner
(Figure 6B). To confirm these results, we immunoprecipated
PP2A from the lysate onto protein A agarose beads and measured
the phosphatase activity of immunoprecipitated PP2A towards
pNPP. All concentrations of QA tested decreased phosphatase
activity by approximately 30%. The decrease was, however, not
dose dependent (Figure 6C). To confirm these results, and to
investigate if this apparent change in phosphatase activity was due
to a change in protein expression, we measured the expression
levels of PP1, PP2A, PP2B and PP5 by Western blot analyses in
the lysate of neurons treated with various concentrations of QA.
The results are shown in Figure 7. As shown in Figure 7A,Q A
treatment decreased the expression of PP1 in a dose dependent
manner. QA at a relatively lower concentration of 400 nM
decreased PP1 expression to the same extent as achieved by
100 nM OA. A similar dose-dependent decrease in the expression
of PP2A (Figure 7B and 7C) and PP5 (Figure 7E) was also
observed with QA acid treatment. PP2B expression on the other
hand was increased by all concentrations of QA tested
(Figure 7D). Maximum increase (,200% of control) was
observed with 200 nM QA. OA treatment also increased PP2B
expression.
These results strongly support the hypothesis that the excito-
toxin QA induces tau phosphorylation by inhibiting the activity
and/or expression of multiple serine/threonine protein phospha-
tases (PP1, PP2A and PP5). Our data also suggest that the
apparent observed increase in total phosphatase activity in the
neuronal lysate treated with relatively lower concentrations of QA
(up to 200 nM) may be due to an increase in PP2B expression
and/or activity.
Quinolinic Acid-induced tau phosphorylation in cultured
foetal neurons involves the activation of NMDA receptor
Since QA is an NMDA receptor agonist, we investigated the
effect of other NMDA receptor agonists (glutamate and NMDA)
on tau phosphorylation and tested whether the NMDA receptor
antagonists can abrogate QA-induced tau phosphorylation. The
results are shown in Figure 8. NMDA receptor agonists,
glutamate and NMDA at equimolar concentrations (500 nM)
increased tau phosphorylation at serine 199/202 (AT8) and
threonine 231 (AT-180), similar to QA. Phosphorylation of tau at
the AT8 site by QA was inhibited by memantine (500 nM) but not
by AP-5 or MK-801. The combination of all the three antagonists
(cocktail) inhibited tau phosphorylation to some degree but not to
the extent of inhibition by memantine alone. Phosphorylation at
the AT-180 site was inhibited by memantine and MK-801 but not
by AP-5. The antagonist cocktail was less effective in inhibiting
phosphorylation of threonine 231 than memantine or MK-801
Figure 4. QA induces tau phosphorylation at multiple serine and
threonine residues: Primary human foetal neurons were cultured at a
density of 1610
6 cells per well in a 12-well plate in the absence or presence
various concentrations of QA. 100 nM Okadaic acid was used as positive
control for tau phosphorylation. After 72 hours, cells were lysed in RIFA
buffer. The lysate protein resolved in 10% SDS-PAGE and Western blot
performed with the antibodies indicated. Antibodies tested are: A,A T 8
(1:1000 dilution); B, AT180 (1:1000); C, AT270 (1:2000); D, PHF-1 (1:1000).
Signal for total tau was determined with the antibody Tau at 1:1000
dilution. Blots were quantified using the Quantity-One software (Biorad).
Signal for phospho tau epitopes was normalized by the signal for total tau
and the data expressed as percent of the normalized signal in control
cultures. Data presented are the mean (6SD) of five different experiments
with neurons from five different brains. Each graph is accompanied with a
representative blot in which lane 1 is control; lane 2, 100 nM QA; lane 3,
350 nM QA; lane 4, 500 nM QA; lane 5, 1200 nM QA; lane 6, 100 nM
Okadaic acid.
doi:10.1371/journal.pone.0006344.g004
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involve NMDA receptor activation and inhibiting the NMDA
receptors by an antagonist inhibits the effect of QA on tau
phosphorylation.
Quinolinic Acid treatment induces the expression of
genes that are involved in AD pathology and tau
phosphorylation
We investigated the expression of genes related to several
signalling pathways in neuronal cultures treated with QA for
24 hours. Of the 84 genes tested, QA induced the expression of 10
genes (Figure 9 and Table 2) by more than two-fold over the
control cultures. All these 10 genes are linked with AD pathology
and 6 are known to be involved in tau phosphorylation. Details of
the over-expressed genes and their reported roles in AD pathology,
tau phosphorylation and neuroprotection are given in Table 2.
Discussion
We previously found that QA accumulates in AD brain and
interestingly was seen in dystrophic hippocampal neurons [15].
We confirm this here and show co-localization with HPT in
cortical and hippocampal neurons. QA is also seen in non-
neuronal cells (microglia), which is likely to be the source for
neuronal uptake. The present study was designed to assess the
potential effect of QA on tau phosphorylation. In accord with our
hypothesis, we demonstrated that QA increases tau phosphoryla-
tion and so is likely to be a critical factor involved in NFTs
formation and subsequent neuronal death. Ultimately, QA
accumulation could lead to a worsening of AD neuropathogenesis.
Tau is a phosphoprotein that can be phosphorylated at multiple
serine and threonine residues. Hyperphosphorylated tau is assem-
bled into paired helical filaments (PHF) leading to the formation of
NFTs[11]. At least thirty serine/threonine phosphorylation sites
have been identified in abnormally hyperphosphorylated tau from
AD brain[20]. Mechanisms of tau hyperphosphorylation are still not
fully understood. Tau hyperphosphorylation results in the disruption
and disassembly of the microtubules and subsequently in neuronal
death and memory loss[21]. The neuronal disruption of microtu-
bules by hyperphosphorylated tau, which accumulates as PHF in
NFTs, is one of the key features of AD[8,22].
Several neuroinflammatory mediators are able to activate the KP
leading to the production of QA by activated microglia and
infiltrating macrophages[4]. Microglial activation is known to occur
Figure 5. QA treatment induced the aggregation of tau: A: Representative blot showing the presence of a high molecular weight (,165 kDa)
band recognized by the PHF-specific antibody AT270 in response to QA treatment. Treatments are the same as shown in Figure 4. B: Quantitative
estimation of the high molecular weight tau band normalized for total tau. The data presented are the average (6SD) of four experiments from four
different brains and are expressed as the ratio of signal for AT270 to that of signal for total tau.
doi:10.1371/journal.pone.0006344.g005
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attenuates tau pathology[23], providing a potential corroborating
link between microglial products and tangle formation. Interesting-
ly, other excitotoxins such as kainic acid are also able to increase
formation of PHF protein[24]. QA is an NMDA receptor agonist
and represents a potent endogenous excitotoxin. Increases in QA
concentration are known to be associated with several neurodegen-
erative diseases[4,7,25]. We previously reported the presence of QA
in close proximity to NFTs and we also observed that QA
accumulates in vacuoles within the cytoplasm of dystrophic
neurons. We showed here that QA and NFTs are often co-localized
in the brain of AD patients[15,26]. We found that in vitro human
primary neurons can take up exogenous QA (see supplementary
Figure S1) but can only catabolize a limited amount[16]. This is
likely to be due to a rapid saturation of the catabolising enzyme for
QA, quinolinate phosphoribosyltransferase (QPRTase) (EC
2.4.2.19) (Figure 1) (see supplementary Figure S2). We demonstrat-
ed that neuronal QPRTase activity begins to be saturated at QA
concentrations$300 nM. Neurons can take up and catabolise QA
to produce more NAD
+[27], which would provide more energy to
the cell and improve DNA repair[28]. The excessive accumulation
of QA is likely to induce a cytotoxic cascade within neurons[15,26].
Taken together these observations led us to investigate whether
elevated concentrations of QA may contribute to AD neuropa-
thology by leading to tau hyperphosphorylation. We found that in
vitro QA treatment of human primary foetal neurons led to a
substantial increase of tau phosphorylation at multiple positions.
Sites S199/202, T231 and S396/404 are more sensitive to
phosphorylation induced by QA treatment. T181 showed a higher
degree of phosphorylation in the control cultures and phosphor-
ylation at this site was not substantially increased by QA
treatment. However, QA treatment increased the appearance of
a high molecular band (,165 kDa) detected with antibody
AT270, which recognizes pT181. This suggests that QA-induced
phosphorylation at this site may increase the aggregation of tau. It
has been suggested that phosphorylation of tau at S199, S202,
T205, T212, S235, S262 and S404 is required for the
sequestration of normal tau, whereas further phosphorylation at
positions T231 and S396 is needed for self-assembly. Phosphor-
ylation at T181 and T217 are also suggested to be involved in self-
assembly[29]. Whether other serine or threonine residues that are
usually phosphorylated in ADP-tau are also phosphorylated by
QA treatment remains to be investigated.
The alternative splicing of the tau gene produces six isoforms of
tau in adult brain. The six isoforms of tau differ from each other
by the presence or absence of one or two inserts in the N-terminal
part and by the presence of either three or four repeats in the C-
terminal region. Whereas all six isoforms are seen in adult brain,
only the shortest isoform of tau is expressed in foetal brain [20].
Although we tested the effect of QA on foetal tau phosphorylation,
our results can be extrapolated to adult tau for two reasons. Firstly,
about one third of total tau in adult brain is the shortest (foetal)
isoform (0N/3R)[20]; and secondly, most of the phosphorylation
sites in PHF-tau are also phosphorylated in foetal brain
tau[30,31,32]. In the AD brain, tau can be hyperphosphorylated
by either an increase in the activities of one or more serine/
threonine kinases or reduced activity of a phosphoseryl/phospho-
threonyl protein phosphatase(s). The role of the kinases in tau
hyperphosphorylation has been well studied but increase in
activity of any one of these kinases has never been reproducibly
shown in AD brain. Phosphoseryl/phosphothreonyl protein
phosphatases are among the major regulators of the phosphory-
lation of tau[33,34,35]. Impairment of protein phosphatases not
only directly affects the dephosphorylation of tau but may also up-
Figure 6. QA treatment reduces total phosphatase and PP2A
activity in cultured neurons: Neuronal cultures were treated with the
concentrations of QA shown, for 72 hours. Cells were lysed in the
phosphataseactivitybuffer (50 mMTris,pH 7.5,150 mMNaCl,1%NP-40,
1 mM PMSF, 1 mM Benzamidine, 10 mM b-mercaptoethanol (bME),
2 mg/ml aprotinin, 2 mg/ml pepstatin and5 mg/ml leupeptin. A: Total
phosphatase activity was determined using pNPP (10 mM) as a substrate
in 50 mM Tris-HCl, pH 7.4, 0.1 mg/ml BSA, 3 mM CaCl2,1mM calmodulin
and 3 mM MnCl2. The reaction mixture was incubated at 30uC for 30 min
and the absorbance measured at 405 nm. Data shown are the average
(6SD) of three experiments. B: OA-inhibited (PP2A) in the lysate of
neurons treated with QA. Total phosphatase activity towards pNPP was
determined as above in the presence or absence of 10 nM OA. The
difference in the activity lost due the addition of 10 nM OA was
calculated as PP2A activity. C: Activity of immunoprecipitated PP2A
towards pNPP. PP2A was immunoprecipitated from 400 mg lysate
protein with anti-PP2A (clone 1D6). 20 ml of bead were resuspended in
200 ml of phosphatase activity buffer containing 50 mM Tris-HCl, pH 7.4,
3m MM n C l 2 and 10 mM pNPP. The reaction mixture was incubated at
30uC for30 min with occasional mixing.Beads were removed andtheOD
of the clear supernatant was measured at 405 nm. Data from three
separate experiments are shown as mean (6SD).
doi:10.1371/journal.pone.0006344.g006
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phosphorylation dependent[35,36,37,38,39,40].
The major serine/threonine phosphatases in the brain are PP1,
PP2A and PP2B[41,42,43,44]. Although quantitatively PP2B is
the most abundantly expressed in the brain, it represents, due to
specific activity, a small proportion of total brain phosphatases
activity; PP1 and PP2A together account for over 90% of the total
mammalian brain protein phosphatase activity, and any alter-
ation in the activity of these two phosphatases may significantly
affect the phosphorylation state of tau. A decrease of about 20%
in the activities of PP1 and PP2A has been reported in AD
brain[45,46]. The observed increase in QA-induced phosphory-
lation of tau could be due to a decrease in the expression or
activity of the major tau phosphatases. We measured total and
OA-inhibited (PP2A) phosphatase activity in QA-treated neuro-
nal lysate. We also measured the activity of immunoprecipitated
PP2A from QA-treated neuronal lysate. We observed a biphasic
effect on total phosphatase activity, using pNPP as substrate. The
activity was increased at 100 nM QA but higher concentrations
decreased the activity in a dose-dependent manner. However,
PP2A activity (measured indirectly as OA-inhibited phosphatase
activity and directly by immunoprecipitating PP2A and measur-
ing its activity) was markedly decreased in a dose dependent
manner.
We measured the expression level of PP1, PP2A, PP2B and
PP5. QA treatment decreased the expression of PP1, PP2A and
PP5 in a dose dependent manner. These data suggest that the
observed reduction in phosphatase activity and subsequent tau
phosphorylation is due to a decrease in the expression of the
major tau phosphatases. The expression of PP2B, on the other
hand, was markedly increased. The observed increase in total
phosphatase activity with lower concentrations of QA (100–
200 nM) could be due to an increase in PP2B activity. Liu et al.
[44] have reported that PP2A, PP1, PP5 and PP2B account for
,71%, ,11%, ,10% and ,7%, respectively, of the total tau
phosphatase activity of human brain. Increased expression of
PP2B could be a compensatory mechanism for the substantial
decrease in PP2A and PP1 activities. Our results are in
accordance with the published literature reporting the increased
expression of PP2B in AD brain, which is characterized by tau
hyperphosphorylation. Up-regulation of PP2B expression in the
pyramidal neurons of hippocampus in AD brain has been
previously reported[47]. An increase in the catalytic cleavage
and subsequent increase in the activity of PP2B in AD brain has
also been reported[44].
Since QA is an NMDA receptor agonist, we investigated
whether other agonists had a similar effect on tau phosphoryla-
tion. Both glutamate and NMDA increased tau phosphorylation
at sites similar to QA. An increase in tau phosphorylation by
glutamate has been reported previously[48]. We also studied the
effects of various NMDA receptor antagonists on QA-induced tau
phosphorylation. Of the antagonists studied, only memantine
Figure 7. QA treatment decreases the expression of PP1, PP2
and PP5 but increases the expression of PP2B: 20 mg lysate
protein (or 20 ml PP2A-IP beads for Figure 7C) was resolved on 10%
SDS-PAGE, protein transferred on to PVDF membrane and probed with
respective antibodies for each phosphatase. For loading control, the
same membranes were stripped and re-probed with anti-actin
antibody. For PP2A-IP the band of IgG heavy chain was used as
loading control. Graph are mean (6SD) of three experiments (from
three separate brains) and are accompanied by a representative blots.
Each bar of the quantification graph represents the corresponding band
above for each phosphatase.
doi:10.1371/journal.pone.0006344.g007
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tau phosphorylation: Primary cultures of human neurons were treated with 500 nM each of three NMDA receptor agonists (QA, glutamate and
NMDA) and three antagonists (memantine, MK-801 and AP-5). One well (termed as cocktail) was treated with a combination of all the three
antagonists (500 nM each). Control wells were cultured in medium alone. Cells were cultured for 24 hours and were then lysed in RIFA buffer. 20 mg
of protein lysate was resolved on 10% SDS PAGE, transferred onto PVDF membrane and probed with phosphor-specific antibodies AT8 and AT180
(1:100 dilution). Antibody Tau (DAKO, 1:10000) was used for total tau. Quantization data is presented as ratios of AT8 and AT-180 signal to total tau
signal and is the average (6SD) of three experiments. A representative blot is for each graph is shown in the insert.
doi:10.1371/journal.pone.0006344.g008
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MK-801 inhibited tau phosphorylation at AT-180 site but not at
AT8 site, whereas, AP-5 had no effect at either site. Inhibition of
okadaic acid-induced tau phosphorylation to the control level by
memantine but not by other antagonists (5,7-dichlorokynurenic
acid (DK) or with D(-)-2-amino-5-phosphonopentanoic acid (AP)
in organotypic cultures of rat hippocampal slices has been
reported by Li et al.
52 and this observation is consistent with our
findings. In this study memantine also reversed the OA-induced
decrease in PP-2A activity, increase in calcium, calmodulin-
dependent protein kinase II (CaMKII) and cyclin AMP-
dependent PKA activities, the decrease and aggregation of
MAP-2 and the phosphorylation and aggregation of neurofila-
ment heavy/medium (NF-H/M) subunits and inhibited the
neurodegeneration associated with these changes. Memantine is
a low to moderate affinity non-competitive NMDA receptor
channel blocker that leads to functional improvement and reduces
care dependence in moderate to severe AD patients[49,50]. The
NMDA receptor has been reported to be associated with PP-2A
and stimulation of this receptor can lead to the dissociation of PP-
2A from the complex and the reduction of PP-2A activity in
cultured cells[51]. It has been suggested that, in addition to its
activity as an NMDA receptor antagonist, the effects of
memantine might involve modulation of PP-2A signalling, a
property not shared by the other NMDA receptor antago-
nists[48].
Finally, we used PCR array to determine which of the genes
associated with tau phosphorylation may be switched on by QA.
We found that QA at the sub-physiological concentrations found
in amyloid plaques[26] was able to activate 10 genes in primary
human neurons (Fig. 10; table 2). Six of these genes e.g. CDK5,
MYC, WNT1, IL1a, iNOS and BRCA1 are associated with
intracellular pathways known to play a role in tau phosphorylation
(Table 2). The other genes WISP1, LEP, C/EBPB and CSF2 are
known to be associated with neuroprotective mechanisms and are
logically activated in response to QA.
In conclusion, we showed in this study that QA over-production
by activated microglia/macrophages and consequent accumula-
tion in AD brain is likely to be involved in two mechanisms 1)
promotion of tau pathology by inducing tau hyperphosphorylation
and 2) direct excitotoxicity (Figure 10). We propose that a decrease
in major tau phosphatases (PP2A, PP1 and PP5) is a mechanism
for this increased in tau phosphorylation in neurons exposed to
QA at pathophysiological concentrations. This study has identified
Figure 9. Determination of the genes induced by QA in primary cultures of human neurons using PCR arrays: The 3D histogram shows
84 genes tested in the Pathfinder kitH. Only 10 genes (in red) were significantly increased (expression.2x the control). No genes were significantly
decreased.
doi:10.1371/journal.pone.0006344.g009
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open a new therapeutic avenue for treatment of AD.
Supporting Information
Figure S1 QA uptake by human neurons in vitro. These data
demonstrate that QUIN is taken up by human primary neurons in
vitro.
Found at: doi:10.1371/journal.pone.0006344.s001 (0.29 MB
PDF)
Figure S2 Determination of QPRTase activity in human
neuron. We developed a new method to quantify QPRTase
activity and we found that neuronal QPRTase activity starts to be
saturated at concentrations above 300 nM.
Found at: doi:10.1371/journal.pone.0006344.s002 (0.15 MB
PDF)
Figure S3 Intracellular co-localization of neurofibrillary tangle
and QA in a human neuron. Serial optical sections were taken
through the neuron at 2 mm intervals. QA (red; Alexa 647) and tau
(AT8; green; Alexa 594).
Found at: doi:10.1371/journal.pone.0006344.s003 (0.60 MB
PDF)
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Table 2.
Genes Increase Genebank Functions Link with AD’s pathology
BRCA1
(Breast cancer 1)
2.64 NM_007294 Cell cycle control. BRCA1 is a
regulator of cell cycle
BRCA1 is found strongly expressed in all Alzheimer’s
brainspecificallyin neurofibrillarytangles.BRCA1is also
linked with prevalence for Alzheimer’s disease[52].
MYC
(c-myc myelocytomatosis viral oncogene)
2.16 NM_002467 Multifunctional nuclear
phosphoprotein involved in
cell cycle progression, apoptosis
and cellular transformation.
Strong c-Myc immunoreactivity is associated with
dystrophic neurites and neurons with NFT. Correlation
between increased Tau phosphorylation and c-myc
over expression in rat primary neurons[53,54].
WNT1
(Wingless-type MMTV integration site family 1)
2.45 NM_005430 Implicated in oncogenesis,
migration, adhesion and in
several developmental processes,
WNT1 interferes with PP2A activity leading to tau
protein hyperphosphorylation. Wnt signalling
pathway links both amyloid plaques biogenesis and
neurofibrillary changes observed in AD
brains[55,56,57].
WISP1
(WNT1 inducible signalling pathway protein 1)
2.39 NM_003882 Involved in developmental
processes and cell proliferation
WISP1 attenuates p53-mediated apoptosis through
activation of the Akt kinase. It is neuroprotective as
WISP1 phosphorylates GSK-3b and maintains b-
catenin to enhance neuronal survival and suppress
microglial activation in AD pathogenesis[56,57].
CDK5
(Cyclin-dependent kinase 5)
3.71 NM_014207 Cdk5 is an atypical cyclin-dependent
kinase localized in the brain
CDK5 is involved in the regulation of tau
phosphorylation[58].
IL1A
(Interleukin 1 a)
2.14 NM_000575 Pleiotropic cytokine involved in
various immune responses,
inflammatory processes, and
hematopoiesis.
Polymorphism of these genes is associated with
Alzheimer’s disease. IL1-a induces tau
phosphorylation in human astrocytes[59].
NOS2A
(Nitric oxide synthase 2A)
4.29 NM_000625 Commonly known as iNOS, it is
inducible by LPS and inflammatory
cytokines.
NOS2A/iNOS protein level is significantly increased
in AD patients leading to oxidative stress. NO
triggers tau hyperphosphorylation in hippocampal
neurons. iNOS immunoreactive profiles were
detected associated with senile plaques and
extracellular neurofibrillary tangles[60,61].
C/EBPB
(CCAAT/ enhancer binding proteinb)
2.38 NM_005194 The C/EBP is implicated in cellular
injury and regeneration in neuron.
C/EBP has been reported to be up regulated in AD.
Activation of NMDA receptors leads to an increase
of C/EBPb expression, which is associated with a
neuroprotective anti-oxidative response and
expression of regeneration-associated genes in
neuron[62,63].
CSF2
(Colony stimulating factor 2 or GM-CSF)
2.17 NM_000758 Cytokine stimulating microglial cell
growth and exerting inflammatory
properties.
Significantly increased CSF levels of GM-CSF in AD.
GM-CSF is associated with neuroprotection and
neuroplasticity[64,65].
LEP
(Leptin)
2.14 NM_000230 Linked to severe and morbid
obesity. In the brain, it’s linked to
synaptic plasticity.
Leptin dysregulation is associated with enhanced
susceptibility of neurons to damage and it has been
found to be neuroprotective in neurodegenerative
brain regions[66].
doi:10.1371/journal.pone.0006344.t002
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